The ROE as of September 2024 (TTM) for Xencor, Inc. (XNCR) is -28.21%

According to Xencor, Inc.’s latest financial reports and current stock price. The company's current ROE is -28.21%. This represents a change of 285.43% compared to the average of -7.32% of the last 4 quarters.

Xencor, Inc. (XNCR) Historical ROE (quarterly & annually)

How has XNCR ROE performed in the past?

The mean historical ROE of Xencor, Inc. over the last ten years is -8.36%. The current -28.21% ROE has changed 237.52% with respect to the historical average. Over the past ten years (40 quarters), XNCR's ROE was at its highest in in the June 2016 quarter at 22.61%. The ROE was at its lowest in in the June 2024 quarter at -11.69%.

Xencor, Inc. (XNCR) ROE by Quarter and Year

Discovering the peaks and valleys of Xencor, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Xencor, Inc. (XNCR) Average ROE

How has XNCR ROE performed in the past?

The current ROE of Xencor, Inc. (XNCR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Xencor, Inc. (XNCR) ROE vs. Peers

How is XNCR’s ROE compared to its peers?

Xencor, Inc.’s ROE is greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Keros Therapeutics, Inc. (-44.73%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Erasca, Inc. (-131.94%), greater than Kura Oncology, Inc. (-40.43%), less than Protagonist Therapeutics, Inc. (85.47%), greater than Merus N.V. (-36.33%), greater than Replimune Group, Inc. (-52.15%), greater than Cerevel Therapeutics Holdings, Inc. (-98.94%), greater than IDEAYA Biosciences, Inc. (-20.53%), greater than AnaptysBio, Inc. (-255.67%), greater than MeiraGTx Holdings plc (-86.28%), greater than Homology Medicines, Inc. (-100.91%), greater than Nuvalent, Inc. (-28.83%), greater than DICE Therapeutics, Inc. (-102.37%), greater than Arcellx, Inc. (-12.42%), greater than Vaxcyte, Inc. (-30.07%), greater than Viridian Therapeutics, Inc. (-49.65%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Sutro Biopharma, Inc. (-97.19%),

Build a custom stock screener for Xencor, Inc. (XNCR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xencor, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Xencor, Inc. (XNCR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Xencor, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.